Efferon
Efferon is a company in Tuttlingen, Germany.
What is sepsis?
“Sepsis is the body's life-threatening response to infection, in which the immune system damages its own tissues and organs while fighting the infection. If left untreated, sepsis can progress to septic shock and multiple organ failure. Globally, sepsis is implicated in nearly one in five deaths, with roughly 48.9 million cases and 11 million deaths each year.”
在公司资料中查看What is hemoadsorption and how does Efferon technology work?
“Hemoadsorption is an extracorporeal blood purification technique that passes a patient's blood through a cartridge containing an adsorbent that selectively binds harmful molecules. Efferon devices use a proprietary multimodal adsorbent that simultaneously removes endotoxin (LPS) and inflammatory cytokines, the two main drivers of systemic inflammation in sepsis and septic shock.”
在公司资料中查看Is Efferon NEO approved for use in children?
“Yes. Efferon NEO received the CE MDR mark in April 2026 and is the first multimodal extracorporeal blood purification device specifically approved in Europe for pediatric patients with sepsis and septic shock from 1 month of age. In the multicenter LASSO NEO trial (NCT05707494) Efferon NEO significantly reduced 28-day mortality (9% versus 35% in controls).”
在公司资料中查看